Infective endocarditis after renal transplantation.

BACKGROUND: Infective endocarditis (IE) is a serious complication in immunosuppressive patients that has adverse effects. OBJECTIVES: The aim of this study was to define the characteristics, outcomes, and correlating factors of mortality in renal transplant recipients. PATIENTS AND METHODS: Infective endocarditis was diagnosed in 22 patients from three renal transplant centers in Iran between 2000 and 2010. Modified Duke criteria were applied to confirm the diagnosis. RESULTS: Twenty-two renal transplant patients with IE were evaluated. Blood culture results were positive in 81%. Enteroccous and group D non-enterococcal were the causative microorganisms in 31% and 25% of patients, respectively. In-hospital and 12-month mortality was 41% and the mortality rate was higher in older patients in comparison to younger patients. Overall, the rates of one-year disease-free patient and graft survival were 49% and 88%, respectively. CONCLUSIONS: Despite the availability of different and potent antibiotics, the mortality caused by IE remains considerably high. These patients are significantly prone to endovascular infections that affect the mortality and survival.

Prevalence of hepatitis B infection in rheumatoid arthritis patients.

Rheumatoid arthritis is a progressive and destructive inflammatory disease of the joints. They had increased mortality depend to use of immunosuppressive drugs. Hepatitis B virus infection is also a health problem in the world. Iran is moderate prevalence endemic area for Hepatitis B virus and it is come too reduced recently by children vaccination. Aim of this study is determined prevalence and screening of Hepatitis B virus infection in rheumatoid arthritis patients. This study is a descriptive cross-sectional which all patients with rheumatic arthritis recruited to study in Tehran in 2012. Then HbsAg and HbcAb assayed for each subjects. In 268 rheumatoid arthritis patients which (82.2%) were female and the average age is 46 +/- 14 years old. HbsAg and HbcAb were positive in 4 (1.49%) and 9 (3.35%), respectively. Only between duration of rheumatoid arthritis and HbcAb had significant association (p < 0.014). The present study highlights Rheumatoid arthritis patients treated with immunosuppressive drugs are at increased risk to reactivation of hepatitis B virus, so screening for Hepatitis B virus infection should be performed prior to immunosuppressive therapy.

Is evaluation of hepatitis a immunity required or not?

Hepatitis A virus (HAV) infection is one of the most common causes of acute hepatitis and it is a serious health problem worldwide. HAV infection is a vaccine preventable disease that can produce the lifelong immunity seen in many developed countries with the vaccination schedule administered to children; however this vaccine is not used in developing countries at the present time. Improvements in food and water hygiene have caused a displacement of hepatitis A infection from children to adults which has increased mortality rates. Therefore evaluation of HAV immunity levels can help health authorities develop polices for prophylaxis especially in developing countries.

High hepatitis B virus load in a patient with severe polyarthritis nodosa.

One of the extra-hepatic manifestations of hepatitis B virus is polyarteritis nodosa (PAN). It may involve medium- and small-sized arteries in any organ. Concurrency of these two diseases may be life threatening and both should be treated. Herein, we report on a patient with severe PAN and high hepatitis B virus load. The patient was an 18-year-old boy with multiple progressive wounds in the skin, referred to our center. The preliminary evaluation showed vasculitis in the skin biopsy compatible with PAN. He was treated with low dose prednisolone and lamivudine for three years. However, his condition got worse and ulcers on his leg became life threatening. The viral load was 17,000,000 copy/mL. The wound developed superimposed resistant bacterial infection. The patient was then treated with two antiviral drugs-lamivudin 100 mg/day plus adefovir 10 mg/day-and high dose cyclophosphamide (750 mg, once a month) and prednisolone (60 mg/day for one month). After six months of treatment, viral load decreased to 100,000 copy/mL and wounds healed. We concluded that high viral load of hepatitis B virus may play an important role in the severity of PAN. We recommend combination therapy with two antiviral agents with high dose of immunosuppressive drugs until both the diseases resolve significantly.

Hepatitis B core antibody in blood donor in Sistan-Balutuestan province of Iran.

BACKGROUND: Safety of blood donor is an important issue for a recipient of blood so all blood donors are to screened for viral such as HBV, HCV, and HIV. Nevertheless, infections sometime occur by blood and its products. OBJECTIVE: Because we haven't got any awareness about isolated Hbc Ab from a blood donor who presented of occults B hepatitis which can transmit infection to blood recipient, we decided to evaluate HbcAb in a blood donor in this province. MATERIALS AND METHODS: This is a cross-sectional study on a blood donor in Sistan-Balutuestan province in southeast of Iran in 2010. All individuals referred for blood donation recruited to this. After consent demographic data was recorded from each case, 5 ml blood sample was drawn and centrifuged to separate out the serum and then HbsAb, HbcAb was assayed. Data analyzed by SPSS 16 and frequency, chi- square test, and Fisher exact test was used and if P > 0.05 it was accented as significant association. RESULT: All individuals were men with age 55 10.5 years. The number of people who had free job was 149 (34.6%) and the number of people whose education level was diploma was 159 (36.9%). About 423 (98.1%) lived in urban areas. The mean weight of men was 76.6 13.7; about 259 (60.1%) men were married. A total of 22 (5.1%) had a positive smoking history. HBc Ab was positive in 87 (20.2%). Nearly all people had HBsAb titer more than 10 IU/L. CONCLUSION: This study showed that some of the blood donors had isolated HbcAb positive therefore we recommend HbcAb screening for blood donation.

Long term effects of one or two doses of hepatitis B vaccine in adults after five years.

The aim of this study is to evaluate hepatitis B vaccine protection in those adults who have taken one or two does of vaccine before. It was a retrospective cross sectional study was conducted on fifty-six military personnel in Tehran, Iran in the spring 2007. Demographic data such as age, marital status, education level, number of vaccine doses injected and, type of vaccine and date of last vaccination was collected. Their serum was tested for HBs Ab, HBc Ab and HBs Ag and finally the results were analyzed by SPSS software. All individuals were male with the mean age of 33.9+/-8.9 years. Twelve individuals who had only received one dose of injected vaccine had no antibody against HBsAg and no protection against hepatitis B virus. Of forty-four individuals that had received two doses of injected vaccine, 27 persons (61.4%) were protected and had serum HBsAb more than 10 MIU mL(-1). In conclusion one dose of HBV vaccine cannot produce immunity for five years but two doses of HBV vaccine can produce immunity for five years. However, HBsAb should be tested to make sure of immunity.